Turn Therapeutics Inc. (TTRX) stock
Close on Nov 11, 2026Market cap $314.86MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $314.86M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 55.31
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$12.77M
- EPS, diluted
- -$0.43
- Book value per share
- $0.19
- Diluted shares
- 30M
Trading
- Next earnings
- Mar 30, 2027 (estimated, after the close)
- Previous close
- $9.92
- Open
- $10.11
- Day's range
- $9.93 – $11.18
- Volume
- 56,973
- Average volume (20 days)
- 95,279
- 52-week range
- $2.57 – $16.45
- RSI (14 days)
- 50.1
- Volatility (1 year)
- 99.9%
- Relative volume
- 0.50×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TTRX | S&P 500 | Difference | TTRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.9% | -2.4% | −9.5 pts | ||
| 3 months | +3.4% | -1.2% | +4.6 pts | ||
| Year to date | +168.3% | +12.3% | +156.0 pts | ||
| 1 year | +172.4% | +12.4% | +160.0 pts | ||
| 3 years | +52750.0% | +78.8% | +52671.2 pts | +708.5% | +21.4% |
| 5 years | +52750.0% | +75.2% | +52674.8 pts | +250.4% | +11.9% |
| 10 years | +52750.0% | +311.1% | +52438.9 pts | +87.2% | +15.2% |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Turn Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- Update
- Results
About Turn Therapeutics
Pharmaceutical Preparations
Turn Therapeutics Inc. develops non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases and fungal infections. Its lead investigational drug candidate, GX-03, targets moderate-to-severe eczema and onychomycosis using a polyhexanide formulation. The company also develops medical devices based on this formulation for acute wound management, dermatitis care, and antimicrobial wound dressings. Additionally, it conducts exploratory research on a thermostable intranasal vaccine platform. The company's business model centers on licensing its medical devices to commercial healthcare partners, including Medline and MiMedx, while directing internal resources toward clinical drug development.
Company profile, executives and historyTurn Therapeutics stock: common questions
What is Turn Therapeutics's stock price?
TTRX closed at $10.57 on Nov 11, 2026, up 6.55% on the day. Over the past 52 weeks it traded between $2.57 and $16.45.
What is Turn Therapeutics's market cap?
Turn Therapeutics was worth $314.86M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TTRX's P/E ratio?
Turn Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.43), so it has no meaningful P/E ratio.
Does Turn Therapeutics pay a dividend?
No. Turn Therapeutics has not paid a cash dividend over the last twelve months.
When does Turn Therapeutics report earnings next?
Turn Therapeutics is expected to report Q4 FY2026 results on Mar 30, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has TTRX stock performed over the past year?
Including dividends, TTRX returned +172.4% over the past year, against +12.4% for the S&P 500.
How many TTRX shares are sold short?
1M shares were sold short at the latest FINRA report, 3.89% of the float, or 5.9 days of average trading volume.
Who are Turn Therapeutics's competitors?
Companies most similar to Turn Therapeutics by business, industry and size include ACRS, MLTX, ANTX, CNTB, EDSA.
See a number that looks wrong?